UNASSIGNED: This meta-analysis reviewed studies on N-TACE before surgical resection vs. liver resection (LR) single large hepatocellular carcinoma (SLHCC) up to March 2023 from four online databases.
UNASSIGNED: Five studies with 1,556 patients were analyzed. No significant differences between N-TACE and LR groups were observed in 1-, 3-, or 5-year overall survival (OS) and disease-free survival (DFS). No significant differences were noted in intraoperative blood loss between groups. Subgroup analysis showed favorable 1-, 3-, and 5-year OS with combination chemotherapy N-TACE (combination group), and better 1-year OS in the LR group with single-agent chemotherapy N-TACE (single-agent group). Five-year DFS favored LR in the single-agent group, and N-TACE in the combination group.
UNASSIGNED: Managing SLHCC requires intricate considerations, and the treatment strategies for this challenging subgroup of HCC need to be improved. The influence of N-TACE on long-term survival depends on the specific chemotherapy regimen employed, and its impact on intraoperative blood loss in SLHCC appears limited.
■这项荟萃分析回顾了手术切除前N-TACE的研究与到2023年3月,来自四个在线数据库的肝切除术(LR)单个大肝细胞癌(SLHCC)。
■分析了5项包含1,556名患者的研究。N-TACE和LR组之间在1-,3-,或5年总生存期(OS)和无病生存期(DFS)。两组之间的术中失血量没有显着差异。亚组分析显示有利的1-,3-,联合化疗N-TACE(联合组)的5年OS,单药化疗N-TACE(单药组)LR组的1年OS较好。五年DFS在单代理人组中偏爱LR,和N-TACE在组合组中。
■管理SLHCC需要复杂的考虑因素,对于这个具有挑战性的HCC亚组的治疗策略需要改进。N-TACE对长期生存的影响取决于所采用的特定化疗方案,其对SLHCC术中失血的影响似乎有限。